BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 3519263)

  • 1. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.
    Douay L; Gorin NC; Mary JY; Lemarie E; Lopez M; Najman A; Stachowiak J; Giarratana MC; Baillou C; Salmon C
    Exp Hematol; 1986 Jun; 14(5):358-65. PubMed ID: 3519263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?
    Jansen EM; Hanks SG; Terry C; Akard LP; Thompson JM; Dugan MJ; Jansen J
    Transfusion; 2007 May; 47(5):817-23. PubMed ID: 17465946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
    Rowley SD; Piantadosi S; Marcellus DC; Jones RJ; Davidson NE; Davis JM; Kennedy J; Wiley JM; Wingard JR; Yeager AM
    Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of bone marrow cryopreservation in chronic granulocytic leukemia: relation to excessive granulo-macrophagic progenitor pool.
    Douay L; Lopez M; Gorin NC; Nauman A; Giarratana MC; Laporte JP; Stachowiak J; Salmon C; Duhamel G
    Int J Cell Cloning; 1986 Jul; 4(4):250-62. PubMed ID: 2875118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.
    To LB; Roberts MM; Haylock DN; Dyson PG; Branford AL; Thorp D; Ho JQ; Dart GW; Horvath N; Davy ML
    Bone Marrow Transplant; 1992 Apr; 9(4):277-84. PubMed ID: 1350938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation.
    Bacigalupo A; Piaggio G; Podesta M; Figari O; Benvenuto F; Sogno G; Tedone E; Raffo MR; Grassia L; Ferrero R
    Bone Marrow Transplant; 1995 Feb; 15(2):221-6. PubMed ID: 7773210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
    Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
    Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Kinetics of hematopoiesis after high-dose chemotherapy and autologous peripheral stem cell transplantation].
    Mayer J; Korístek Z; Pospísil Z; Vásová I; Adam Z; Hájek R; Krejcí M; Král Z; Navrátil M; Vorlícek J; Bourková L; Matýsková M; Adler J; Vinklárková J; Klabusay M; Koutná I; Hoffová V; Schmitzová D; Janovská E
    Cas Lek Cesk; 1999 Mar; 138(6):170-7. PubMed ID: 10510531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
    Stewart FM; Kaiser DL; Ishitani KP; Pirsch GW; Niskanen E
    Exp Hematol; 1989 Oct; 17(9):974-80. PubMed ID: 2673831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.